Varian Acquires Polymer Laboratories
News Nov 09, 2005
Varian, Inc. has announced that it has acquired PL International Limited, and its subsidiaries including Polymer Laboratories Ltd. for approximately $42 million in cash net of acquired cash, subject to certain net asset adjustments.
The transaction also includes an opportunity for additional purchase price payments over three years, depending on future financial performance. Those future payments could total up to $23 million if aggressive performance targets are achieved.
For HPLC, Polymer Laboratories manufactures polymeric media and columns for biochromatography, and specialist detectors.
For the pharmaceutical and clinical diagnostic industries, Polymer Laboratories manufactures resins for drug development and pharmaceutical process applications, and clinical diagnostic polymer particles.
“The acquisition of Polymer Laboratories is strategic to the advancement of Varian’s goal to grow the applications-based consumable products to become a larger portion of the business,” said Garry W. Rogerson, President and CEO, Varian, Inc.
“Polymer Laboratories is a world leader in polymer-based consumables, allowing us to offer customers complete solutions for the purification, separation, and preparation of polymers, including proteins.”
“We are also excited about Polymer Laboratories’ HPLC detectors, one of which, the evaporative light scattering detector, is well suited for operation together with mass spectrometers and will enhance our information rich detectors product lines.”
Polymer Laboratories generated revenues of approximately $22 million for the twelve months ended September 30, 2005.
Added G. Edward McClammy, Senior Vice President, Chief Financial Officer and Treasurer, Varian, Inc., “For the first three to six months, Polymer Laboratories should be neutral to pro forma earnings per share with revenues at historical run rates.”
“After this transition period, we anticipate the acquisition to be accretive and revenues to grow faster than our average.”
“The sale of Polymer Laboratories to Varian is a win-win situation for both companies,” said Dr. Frank Warner, Chairman of Polymer Laboratories.
“It has been our intention to be acquired by a company with strategic benefits utilizing the broad spectrum of technologies within our company, and which would give us the opportunity to grow our portfolio and provide greater opportunities to our skilled staff.”
“I firmly believe that Varian's global infrastructure will provide a platform for maximum growth at a faster rate than might otherwise have been possible.”
GPC is an analytical high performance liquid chromatography technique used to separate components based on their molecular size in solution.
It is the technique of choice for rapid and reliable characterization of polymer molecular weight and molecular weight distributions.
This acquisition is part of Varian, Inc.'s strategy to strengthen the Company's product portfolio, especially in the focus area of laboratory consumables, with internal research and development efforts and strategic acquisitions of complementary products and technologies.
Varian, Inc. will be hosting an investor luncheon in New York on Tuesday, November 15, 2005 at 12:30 p.m. Eastern Time, to discuss the company’s strategic direction, including the acquisition of Polymer Laboratories.
The meeting will be webcast and may be heard via the Internet by going to company website.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE